

Editorial

Cite this article: Healy D (2020). Post-SSRI sexual dysfunction & other enduring sexual dysfunctions. *Epidemiology and Psychiatric Sciences* **29**, e55, 1–2. <https://doi.org/10.1017/S2045796019000519>

Received: 10 July 2019

Revised: 19 August 2019

Accepted: 31 August 2019

Key words:


Adverse effects; antidepressants; drug side effects other; sexual dysfunction

Author for correspondence:

David Healy,

E-mail: David.Healy54@googlemail.com

Post-SSRI sexual dysfunction & other enduring sexual dysfunctions

David Healy 

Bangor University, Psychiatry, Bangor, Gwynedd, UK

Abstract

Enduring sexual difficulties following treatment with selective serotonin reuptake inhibitor antidepressants have been reported to regulators since 1991, but it was only in 2006 that a formal post-SSRI sexual dysfunction syndrome was reported. The clinical, research and regulatory implications of this syndrome are considerable and researchers using epidemiological methods are well placed to map out the contours of the problem and perhaps pinpoint possible treatments.

Introduction

Close to 100% of takers of a selective serotonin reuptake inhibitor (SSRI) have a degree of genital sensory change within 30 min of taking. These effects consist primarily of a reduced sensitivity, often termed ‘numbing’ by those affected but others have genital arousal (irritability). The reduced sensitivity is accompanied by an immediate delay of ejaculation in men and muting of orgasm in both men and women. After a period of treatment, orgasm may stop and there may be a loss of libido (Healy *et al.*, 2018a).

The ‘numbing’ effect produced by SSRIs has similarities to the effect of rubbing lidocaine into the genital area, which was a prior treatment for premature ejaculation, and SSRIs in single doses are used for premature ejaculation now. The effect is also described in terms of a loss of pleasurable sensation. In some cases, there is an actual genital numbing equivalent to that produced by lidocaine.

These immediate onset sexual effects ordinarily lift when treatment stops. In 2006, reports appeared of a condition now termed post-SSRI sexual dysfunction (PSSD), in which the genital numbing, pleasureless or absent ejaculation/orgasm, and loss of libido remain and may become more pronounced after treatment stops (Bahrick, 2006; Csoka and Shipko, 2006). PSSD can persist for decades afterwards (Healy *et al.*, 2018a, 2018b).

In 2001, persistent genital arousal disorder (PGAD), an enduring disorder of irritable genital sensation was described (Leiblum and Nathan, 2001). This condition is not linked to enhanced libido and does not stem from psychological issues. At present PGAD appears to affect women more than men. This condition seems more likely to happen around the menopause, and while closely related to discontinuation from SSRI medication, can also occur following trauma to the genital area (Healy *et al.*, 2018a).

These genital effects do not occur on antidepressants that do not inhibit serotonin reuptake; other antidepressants and psychotropic drugs can cause erectile dysfunction but not the syndromes of numbness, pleasureless orgasm, loss of libido or persistent arousal.

Two other syndromes have been described which appear closely related to PSSD. One is post-finasteride syndrome (PFS). First described in 2011, this occurs in young men taking finasteride to stall hair loss (Irwig and Kolukula, 2011). It also occurs with other 5- α reductase inhibitors – dutasteride and saw palmetto. Genital anaesthesia, loss of libido and sexual dysfunction are features of this syndrome. Initial finasteride treatment can produce some sexual dysfunction, but this is less common when compared with SSRIs. It is unclear if the sexual dysfunction that appears on treatment is continuous with PFS or distinct from it.

A post-retinoid sexual dysfunction (PRSD) has also been described (Hogan *et al.*, 2014). This also includes genital anaesthesia, sexual dysfunction and loss of libido. There can be some sexual dysfunction on initial treatment in patients taking isotretinoin for acne, but it is not clear what continuity there may be between this and PRSD.

These enduring post-treatment syndromes may interface with tardive dyskinesia linked to antipsychotic drugs in the 1960s. Antipsychotics can cause dyskinesias on treatment, which ordinarily resolve when treatment is stopped. Dyskinesias can also emerge on withdrawal but clear up in time. Tardive dyskinesia is a syndrome that involves dyskinetic movements centred on the jaw and lower facial area, which can emerge on treatment but become more marked when treatment stops. The syndrome can endure for years or decades afterwards.

These legacy effects of antidepressants and antipsychotics have some interface with withdrawal syndromes linked to these drugs. Withdrawal to opioids and alcohol is viewed as

© The Author(s) 2019. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is included and the original work is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use.

limited to a few weeks, having features not found during administration of the drug and as ordinarily responding to re-institution of treatment. Antidepressant and antipsychotic withdrawal however is linked to dysthymia, which may appear to be continuous with the original problem but can be demonstrated in healthy volunteers given these drugs, as well as to other sensory and autonomic disturbances. These states can last for months or longer, opening up a possible link between enduring sexual syndromes and other legacy effects of antidepressants and antipsychotics (Healy and Tranter, 1999).

There are variations among antidepressants and antipsychotics in their likelihood of causing withdrawal problems and likelihood of causing tardive syndromes but the basis for these differences is not understood.

Mechanisms

PSSD occurs in all ages, both sexes and all ethnic groups. It can begin after a few doses of treatment or only become apparent after years of exposure (Healy *et al.*, 2018a).

There are two issues to account for. One is the original sensory changes. These almost certainly extend beyond the genital area but are more salient there perhaps because of the functional consequences. SSRIs also produce a more general dampening of reactivity – commonly termed emotional numbing. This ‘numbing’ may be linked to the pronounced sensory features that characterise the SSRI withdrawal syndrome, which may be rebound effects that include spontaneous orgasms and can result in PGAD.

At present, there is no agreement as to how the sensory changes on SSRIs come about. Lidocaine, which also produces genital numbing, appears to do so through an action on late sodium currents (Johannesen *et al.*, 2016) and serotonin reuptake inhibitors also have effects on late sodium currents (Wang *et al.*, 2008). Antidepressants with effects on late sodium currents are also widely used to treat neuropathic pain.

Aiming at finding a treatment, PSSD sufferers have tried a wide range of agents active on various dopamine and serotonin receptors along with phosphodiesterase inhibitors, and other drugs, but these have no therapeutic effect for PSSD, PFS or PRSD.

PFS sufferers have focused on evidence for androgen insensitivity. It is also the case that SSRIs reduce testicular volume and sperm counts but these effects appear to occur in the absence of PSSD. At present, no endocrine manipulations appear to make a difference in PFS, PSSD or PGAD.

The treatment approaches adopted to date have been largely targeted at reversing the acute sexual effects rather than reversing the mechanism that leads to enduring effects. This is similar to research efforts on tardive dyskinesia which for 4 decades have focused on the dopamine system without finding an answer.

A second issue therefore is one of pinpointing a mechanism that might underpin enduring effects like these. It does appear that with time (several years) a degree of spontaneous recovery happens in some cases. In other cases, there are brief remissions (days), often triggered by stopping a brief course of another drug such as an antibiotic. There are grounds to think therefore that these enduring effects do not stem from permanent damage.

Is this problem best seen as physiological (bio-electric) or pharmacological? Is the site at which the original sensory changes are effected central or peripheral? Do they arise in a central

nucleus, at the dorsal root ganglion level, or from local treatment effects on C-fibres?

Future research

In June 2019, the European Medicines Agency (EMA) acknowledged that sexual dysfunction can persist after treatment with serotonin reuptake inhibiting antidepressants stops. They have asked companies to update their product datasheets accordingly.

Now that this problem has been formally recognised, epidemiology can contribute to finding a solution to these problems. First, using a proxy for PSSD such as prescription of phosphodiesterase inhibitors in young men, it may be possible to offer some indication as to the frequency of these problems. Second, using phosphodiesterase inhibitor use, it may also be possible to track whether any other medicines cause similar problems. On the basis of reports to regulators, it is likely that a number of novel anticoagulants such as rivaroxaban and apixaban along with tetracycline antibiotics may cause similar problems. The greater the number of medicines implicated, the more likely a mechanism will be found. Third, it is quite possible that we already have agents that can make a difference. These are most likely to be detected using databases that shed light on who does not develop these problems.

Acknowledgements. None.

Financial support. None.

Conflict of interest. None.

References

- Bahrack AS** (2006) Post SSRI sexual dysfunction. American society for the advancement of pharmacotherapy. *Tablet (brooklyn, New York, N Y)* **7**, 2–3, 10–11.
- Soka AB and Shipko S** (2006) Persistent sexual side effects after SSRI discontinuation. *Psychotherapy and Psychosomatics* **75**, 187–188.
- Healy D and Tranter R** (1999) Pharmacologic stress diathesis syndromes. Response from H Ashton, A Young and N Ferrier, R Baldessarini, A Viguera and L Tondo, L Hollister, P Haddad and I Anderson, P Tyrer. *Journal of Psychopharmacology* **13**, 287–299.
- Healy D, Le Noury J and Mangin D** (2018a) Citizen petition: sexual side effects of SSRIs and SNRIs. *International Journal of Risk and Safety in Medicine* **29**, 125–134.
- Healy D, Le Noury J and Mangin D** (2018b) Enduring sexual dysfunction after treatment with antidepressants, 5 α -reductase inhibitors and isotretinoin: 300 cases. *International Journal of Risk and Safety in Medicine* **29**, 135–147.
- Hogan C, Le Noury J, Healy D and Mangin D** (2014) One hundred and twenty cases of enduring sexual dysfunction following treatment. *International Journal of Risk and Safety in Medicine* **26**, 109–116.
- Irwig MS and Kolukula S** (2011) Persistent sexual side effects of finasteride for male pattern hair loss. *Journal of Sexual Medicine* **8**, 1747–1753.
- Johannesen L, Vicente J, Mason J and Erato C** (2016) Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. *Clinical Pharmacology and Therapeutics* **99**, 214–223.
- Leiblum SR and Nathan SG** (2001) Persistent sexual arousal syndrome: a newly discovered pattern of female sexuality. *Journal of Sex and Marital Therapy* **27**, 365–380.
- Wang GK, Mitchell J and Wang S-Y** (2008) Block of persistent late Na⁺ currents by antidepressant sertraline and paroxetine. *Journal of Membrane Biology* **222**, 79–90.